p38 MAP kinase inhibitors: A future therapy for inflammatory diseases

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 1, 2006, Pages 49-54

  Mayer, Ruth J ^a   Callahan, James F ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ANTIINFLAMMATORY AGENT; APOPTOSIS SIGNAL REGULATING KINASE 1; CORTICOSTEROID; DORAMAPIMOD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; SB 242235; SB 681323; SCIO 469; STRESS ACTIVATED PROTEIN KINASE; TAK 715; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VX 702;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; INFLAMMATORY DISEASE; LIVER TOXICITY; NONHUMAN; PHARMACODYNAMICS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 33646473843     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.03.003     Document Type: Review

References (39)

1. Lee J.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
2. Polmar, S.H. et al. (2002) Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB-796 BS) administered twice daily for 14 days to healthy volunteers. AAAAI 58th Annual Meeting (Abstract #157)
3. Gupta, A. et al. (2002) Safety, pharmacokinetics and pharmacodynamics of single doses or an oral p38 MAP kinase inhibitor (BIRB-796 BS) in healthy human males a placebo-controlled, randomized study, double-blinded at each dose level. AAAAI 58th Annual Meeting (Abstract #158)
4. Weisman, M. et al. (2002) A double-blind, placebo controlled trial of VX-745, an oral p38 mitogen-activated protein kinase (MAPK) inhibitor in patients with rheumatoid arthritis (RA). 2002 Annual European Congress of Rheumatology, Stockholm, Sweden (Abstract FRI0018)
5. Lee M.R., and Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38 alpha protein. Curr. Med. Chem. 12 (2005) 2979-2994
6. Shieven G.L. The biology of p38 kinase: a central role in inflammation. Curr. Top. Med. Chem. 5 (2005) 921-928
7. Beadmore V.A., et al. Generation and characterization of p38β (MAPK11) gene-targeted mice. Mol. Cell Biol. 25 (2005) 10454-10464
8. Fabian M.A., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
9. Badger A.M., et al. Disease-modifying activity of SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant arthritis. Arthritis Rheum. 43 (2001) 175-183
10. Nishikawa M., et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 48 (2003) 2670-2681
11. Behr T.M., et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and disfunction. Circulation 104 (2001) 1292-1298
12. Liu Y.H., et al. Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J. Card. Fail. 11 (2005) 74-81
13. Underwood D.C., et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 279 (2000) L895-L902
14. Barnes P.J., and Stockley R.A. COPD: current therapeutic interventions and future approaches. Eur. Respir. J. 25 (2005) 1084-1106
15. Sweiter S.M., et al. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 109 (2004) 409-419
16. Hollenback E. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J. 18 (2004) 1550-1552
17. Salmon M., et al. Inhibition of antigen-induced airway inflammation and remodeling in sensitised Brown-Norway rats by SB 239063 a potent and selective p38 MAP kinase inhibitor. Am. J. Respir. Crit. Care Med. 165 (2002) A538
18. Aggarwal B.B., et al. TNF blockade: and inflammatory issue. Ernst Shering Res. Found. Workshop 56 (2006) 161-186
19. Choi M.E. Mechanism of transforming growth factor-beta1 signaling. Kid. Intl. Suppl. 77 (2000) S53-S58
20. Dambach D. Potential adverse effects associated with inhibition of p38α/β MAP kinases. Curr. Top. Med. Chem. 5 (2005) 929-939
21. Fullerton T., et al. Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase. Clin. Pharm. Ther. 67 (2000) 81
22. Parasrampuria D.A., et al. Single-dose pharmacokinetics and pharmacodymanics of RWJ-67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J. Clin. Pharmacol. 43 (2003) 406-413
23. Branger J., et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 168 (2002) 4070-4077
24. Fijen J.W., et al. Inhibition of p38 mitogen-activated protein kinase: a dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit. Care Med. 30 (2002) 841-845
25. Fijen J.W., et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124 (2001) 16-20
26. Vertex Pharmaceuticals (2004) Preliminary Phase IIa data for VX-702 demonstrate tolerability and reduction in C-reactive protein in cardiovascular patients. European Society of Cardiology's Acute Cardiac Care Symposium, Rome, Italy
27. Gaestel M. MAPKAP kinases: MKs two's company, three's a crowd. Nat. Rev. Mol. Cell Biol. 7 (2006) 120-130
28. Manke I.A., et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 17 (2005) 37-48
29. Anderson D.R., et al. Aminocyanopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK2). Bioorg. Med. Chem. Lett. 15 (2005) 1587-1590
30. Wang X., et al. Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J. Biol. Chem. 15 (2002) 43968-43972
31. Shiroto K., et al. MK2-/- gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. J. Mol. Cell. Cardiol. 38 (2005) 93-97
32. Kotlyarov A., et al. Distinct cellular functions of MK2. Mol. Cell. Biol. 22 (2002) 4827-4835
33. Matsukawa J. The ASK-1-MAP kinase cascades in mammalian stress response. J. Biochem. 136 (2004) 261-265
34. Tobiume K., et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO J. 2 (2001) 222-228
35. Winzen R., et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18 (1999) 4969-4980
36. Bulavin D.V. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18 (1999) 6845-6854
37. Dang P.M., et al. Phosphorylation of the NADPH oxidase component p67(PHOX) by ERK2 and P38MAPK: selectivity of phosphorylated sites and existence of an intramolecular regulatory domain in the tetratricopeptide-rich region. Biochemistry 42 (2003) 4520-4526
38. Behr T.M., et al. p38 Mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr. Opin. Invest. Drugs 4 (2003) 1059-1064
39. Miwatashi S., et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J. Med. Chem. 48 (2005) 5966-5979